IPERGAY

IPERGAY was a French clinical trial of pre-exposure prophylaxis (PrEP) in sexually active gay men in a community setting. It demonstrated 86% effectiveness in preventing HIV transmission.[1]

The study was published in December 2015[2] looking at an alternative strategy of "on-demand" PrEP where Truvada was taken 2–24 hours before sexual activity and only continued for 2 days afterwards. In a population of 400 gay men in France and Canada at high risk for HIV, this strategy led to an 86% drop in HIV infections over the average 9 month follow-up of the study. As of December 2015, non-continuous PrEP methods have not been endorsed by WHO or national guidelines.[3][4]

References

  1. ↑ Cairns, Gus (24 February 2015). "Pre-exposure prophylaxis also stops 86% of HIV infections in Ipergay study". Aidsmap. Retrieved 2016-08-02.
  2. ↑ "On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection". New England Journal of Medicine. 373: 2237–2246. December 4, 2015. doi:10.1056/NEJMoa1506273. Retrieved December 18, 2015.
  3. ↑ United States Public Health Service. "Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2014" (PDF). Centers for Disease Control and Prevention.
  4. ↑ "WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)" (PDF). World Health Organization. November 2015. Retrieved December 18, 2015.

See also

External links


This article is issued from Wikipedia - version of the 8/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.